Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Warren Fiskus

Showing results (21-30 of 94) with videos related to

Pageof 10
Sort By:
The Journal of Biological Chemistry|June 7, 2005
Inhibition of histone deacetylase 6 acetylates and disrupts the chaperone function of heat shock protein 90: a novel basis for antileukemia activity of histone deacetylase inhibitorsPurva Bali, Michael Pranpat, James Bradner, et al.
Breast Cancer Research and Treatment|July 25, 2012
Co-treatment with vorinostat synergistically enhances activity of Aurora kinase inhibitor against human breast cancer cellsWarren Fiskus, Stacey L Hembruff, Rekha Rao, et al.
Cancer Research|May 20, 2004
Cotreatment with 17-allylamino-demethoxygeldanamycin and FLT-3 kinase inhibitor PKC412 is highly effective against human acute myelogenous leukemia cells with mutant FLT-3Prince George, Purva Bali, Pamela Cohen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 6, 2006
Cotreatment with vorinostat (suberoylanilide hydroxamic acid) enhances activity of dasatinib (BMS-354825) against imatinib mesylate-sensitive or imatinib mesylate-resistant chronic myelogenous leukemia cellsWarren Fiskus, Michael Pranpat, Maria Balasis, et al.
Leukemia Research|November 7, 2008
Chemotherapy and dasatinib induce long-term hematologic and molecular remission in systemic mastocytosis with acute myeloid leukemia with KIT D816VCelalettin Ustun, Christopher L Corless, Natasha Savage, et al.
Molecular Cancer Therapeutics|February 28, 2012
Combination of pan-histone deacetylase inhibitor and autophagy inhibitor exerts superior efficacy against triple-negative human breast cancer cellsRekha Rao, Ramesh Balusu, Warren Fiskus, et al.
Blood|March 16, 2006
Combined effects of novel tyrosine kinase inhibitor AMN107 and histone deacetylase inhibitor LBH589 against Bcr-Abl-expressing human leukemia cellsWarren Fiskus, Michael Pranpat, Purva Bali, et al.
Molecular Cancer Therapeutics|July 24, 2014
BET protein antagonist JQ1 is synergistically lethal with FLT3 tyrosine kinase inhibitor (TKI) and overcomes resistance to FLT3-TKI in AML cells expressing FLT-ITDWarren Fiskus, Sunil Sharma, Jun Qi, et al.
Molecular Cancer Therapeutics|July 29, 2010
Heat shock protein 90 inhibition depletes TrkA levels and signaling in human acute leukemia cellsRekha Rao, Srilatha Nalluri, Warren Fiskus, et al.
Blood|September 25, 2004
Mechanistic role of heat shock protein 70 in Bcr-Abl-mediated resistance to apoptosis in human acute leukemia cellsFei Guo, Celia Sigua, Purva Bali, et al.
Pageof 10

Showing results (21-30 of 94) with videos related to

Sort By:
Pageof 10
The Journal of Biological Chemistry|June 7, 2005
Inhibition of histone deacetylase 6 acetylates and disrupts the chaperone function of heat shock protein 90: a novel basis for antileukemia activity of histone deacetylase inhibitorsPurva Bali, Michael Pranpat, James Bradner, et al.
Breast Cancer Research and Treatment|July 25, 2012
Co-treatment with vorinostat synergistically enhances activity of Aurora kinase inhibitor against human breast cancer cellsWarren Fiskus, Stacey L Hembruff, Rekha Rao, et al.
Cancer Research|May 20, 2004
Cotreatment with 17-allylamino-demethoxygeldanamycin and FLT-3 kinase inhibitor PKC412 is highly effective against human acute myelogenous leukemia cells with mutant FLT-3Prince George, Purva Bali, Pamela Cohen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 6, 2006
Cotreatment with vorinostat (suberoylanilide hydroxamic acid) enhances activity of dasatinib (BMS-354825) against imatinib mesylate-sensitive or imatinib mesylate-resistant chronic myelogenous leukemia cellsWarren Fiskus, Michael Pranpat, Maria Balasis, et al.
Leukemia Research|November 7, 2008
Chemotherapy and dasatinib induce long-term hematologic and molecular remission in systemic mastocytosis with acute myeloid leukemia with KIT D816VCelalettin Ustun, Christopher L Corless, Natasha Savage, et al.
Molecular Cancer Therapeutics|February 28, 2012
Combination of pan-histone deacetylase inhibitor and autophagy inhibitor exerts superior efficacy against triple-negative human breast cancer cellsRekha Rao, Ramesh Balusu, Warren Fiskus, et al.
Blood|March 16, 2006
Combined effects of novel tyrosine kinase inhibitor AMN107 and histone deacetylase inhibitor LBH589 against Bcr-Abl-expressing human leukemia cellsWarren Fiskus, Michael Pranpat, Purva Bali, et al.
Molecular Cancer Therapeutics|July 24, 2014
BET protein antagonist JQ1 is synergistically lethal with FLT3 tyrosine kinase inhibitor (TKI) and overcomes resistance to FLT3-TKI in AML cells expressing FLT-ITDWarren Fiskus, Sunil Sharma, Jun Qi, et al.
Molecular Cancer Therapeutics|July 29, 2010
Heat shock protein 90 inhibition depletes TrkA levels and signaling in human acute leukemia cellsRekha Rao, Srilatha Nalluri, Warren Fiskus, et al.
Blood|September 25, 2004
Mechanistic role of heat shock protein 70 in Bcr-Abl-mediated resistance to apoptosis in human acute leukemia cellsFei Guo, Celia Sigua, Purva Bali, et al.
Pageof 10